In a bold move to tackle soaring prescription drug costs, President Trump has issued a 60-day ultimatum to 17 major pharmaceutical companies, demanding substantial reductions in U.S. drug prices. Expressing frustration over the high costs that American consumers face, Trump has emphasized the need for these companies to take immediate action, threatening potential consequences, including large tariffs on imported medicines, if they do not comply. The White House has formally reached out to these drugmakers in letters outlining the urgency of this demand, appealing to their sense of corporate responsibility. Critics point out that the claims of achieving significant price reductions may not be realistic, while the pharmaceutical sector has reacted negatively, seeing declines in stock prices following the announcement.